| ZURA BIO LTD CL.A |
| China |
| Gesundheit |
| KYG9TY5A1016 / A3D7LY |
| 94E (Frankfurt) / ZURA (NASDAQ) |
| FRA:94E, ETR:94E, 94E:GR, NASDAQ:ZURA |
| - |
| https://zurabio.com/ |
|
Zura Bio Ltd. is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. The company focuses on advancing a pipeline that includes tibulizumab (ZB-106), a bispecific antibody..
>Volltext.. |
| 495.65 Mio. EUR |
| 400.86 Mio. EUR |
| - |
| -65.14 Mio. EUR |
| -86.07 Mio. EUR |
| -1.03 EUR |
| - |
| 94.78 Mio. EUR |
| -56.15 Mio. EUR |
| 8.82 |
| - |
| -118.91% |
| - |
| - |
| - |
| - |
| ZURA BIO, ZURABIO |
| 05.04.26 |
|